Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Biol Chem ; 279(23): 24355-61, 2004 Jun 04.
Article in English | MEDLINE | ID: mdl-15044445

ABSTRACT

Arterial wall sphingomyelinase (SMase) has been proposed to be involved in atherogenesis. SMase modification of lipoproteins has been shown to occur in atherosclerotic lesions and to facilitate their uptake by macrophages and foam cell formation. To investigate the mechanism of macrophage uptake enhanced by SMase, we prepared lipid emulsions containing sphingomyelin (SM) or ceramide (CER) as model particles of lipoproteins. SMase remarkably increased the uptake of SM-containing emulsions by J774 macrophages without apolipoproteins. The emulsion uptake was negatively correlated with the degree of particle aggregation by pretreatment with SMase, whereas the uptake of CER-containing emulsions was significantly larger than SM-containing emulsions, indicating that enhancement of uptake is due to the generation of CER molecules in particles but not to the aggregation by SMase. Heparan sulfate proteoglycans (HSPGs) and low density lipoprotein receptor-related protein (LRP) were crucial for CER-enhanced emulsion uptake, because heparin or lactoferrin inhibited the emulsion uptake. Confocal microscopy also showed that SMase promoted both binding and internalization of emulsions by J774 macrophages, which were almost abolished by lactoferrin. Apolipoprotein E further increased the uptake of CER-containing emulsions compared with SM-containing emulsions. These findings suggest the generation of CER in lipoproteins by SMase facilitates the macrophage uptake via HSPG and LRP pathways and plays a crucial role in foam cell formation. Thus, CER may act as an important atherogenic molecule.


Subject(s)
Ceramides/metabolism , Heparan Sulfate Proteoglycans/metabolism , Lipid Metabolism , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Macrophages/metabolism , Animals , Anticoagulants/pharmacology , Apolipoproteins E/chemistry , Apolipoproteins E/metabolism , Cell Line , Foam Cells/metabolism , Heparin/chemistry , Heparin/pharmacology , Humans , Hydrolysis , Lactoferrin/chemistry , Lactoferrin/pharmacology , Lipoproteins/metabolism , Mice , Microscopy, Confocal , Time Factors
2.
Chem Phys Lipids ; 126(1): 39-48, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14580709

ABSTRACT

The chylomicron assembly has been proposed to involve the core expansion of apolipoprotein B (apoB)-containing primordial lipoproteins by fusing with triglyceride-rich lipid droplets. We examined the effects of an inhibitor of chylomicron secretion, Pluronic L81, on triolein-phosphatidylcholine emulsions and low density lipoproteins (LDL) which were used for the models of lipid droplets and primordial lipoproteins, respectively. We showed by dynamic light scattering that the sizes of lipid emulsions and LDL were increased in the presence of Pluronic L81. The binding of apoB-100 to lipid emulsions was enhanced by Pluronic L81. CD and fluorescence lifetime measurements revealed that Pluronic L81 altered the secondary structure of apoB-100 with an increased local hydration. The proper hydrophilic-to-hydrophobic balance of Pluronic L81 is important for these actions. It is proposed that Pluronic L81 inhibits the secretion of chylomicrons by leading the excess core expansion of the primordial lipoproteins and the conformational modification of apoB.


Subject(s)
Apolipoproteins B/chemistry , Lipid Metabolism , Poloxamer/pharmacology , Surface-Active Agents/pharmacology , Apolipoproteins B/drug effects , Chylomicrons/antagonists & inhibitors , Emulsions , Humans , Lipoproteins, LDL/metabolism , Particle Size , Protein Conformation/drug effects , Protein Structure, Secondary/drug effects
3.
Biochim Biophys Acta ; 1632(1-3): 31-9, 2003 Jun 10.
Article in English | MEDLINE | ID: mdl-12782148

ABSTRACT

Large (ca. 120 nm) and small (ca. 35 nm) emulsions consisting of triolein (TO) and phosphatidylcholine (PC) were prepared as the primary protein-free models of chylomicrons and their remnants, respectively. Lipoprotein lipase (LPL)-mediated lipolysis of emulsion TO was retarded in chylomicron-free human plasma compared with the hydrolysis activated by isolated apolipoprotein C-II (apoC-II). In 30% plasma, free fatty acid (FFA) release rate was higher for large emulsions than for small ones, while both emulsions were hydrolyzed at similar rates in the presence of isolated apoC-II. Isolated apolipoprotein C-III (apoC-III) or apolipoprotein E (apoE) worked as LPL-inhibitor of the lipolysis activated by apoC-II. It was also observed that apolipoprotein A-I (apoA-I) showed distinct inhibitory effects on the lipolysis of large and small emulsions: more effective inhibition for small emulsions. Kinetic analyses showed that K(m)(app) and V(max)(app) for the lipolysis of emulsions were lower in the presence of 30% plasma than isolated apoC-II. ApoA-I also markedly decreased K(m)(app) and V(max)(app) for LPL-catalyzed hydrolysis of both emulsions. In chylomicron-free serum, the density of bound apoA-I at small emulsion surfaces was about three fold greater than large emulsion surfaces, but the binding densities of apoC-II, apoC-III and apoE were less for small emulsion surfaces than for large ones, suggesting that apoA-I preferentially binds to small particles and displaces other exchangeable apolipoproteins from particle surfaces. These results indicate that, in addition to the well known inhibitory effects of apoC-III and apoE, apoA-I in plasma regulates the lipolysis of triglyceride (TG)-rich emulsions and lipoproteins in a size-dependent manner.


Subject(s)
Apolipoproteins/pharmacology , Emulsions , Lipid Metabolism , Lipolysis/drug effects , Lipoprotein Lipase/metabolism , Animals , Apolipoprotein A-I/metabolism , Apolipoprotein A-I/pharmacology , Apolipoprotein C-II , Apolipoprotein C-III , Apolipoproteins/blood , Apolipoproteins/isolation & purification , Apolipoproteins C/metabolism , Apolipoproteins C/pharmacology , Apolipoproteins E/metabolism , Apolipoproteins E/pharmacology , Cattle , Enzyme Activation/drug effects , Humans , Hydrolysis , In Vitro Techniques , Kinetics , Lipoprotein Lipase/drug effects , Milk/enzymology , Phosphatidylcholines/metabolism , Protein Binding , Triolein/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...